Abstract
We recommend that Jemperli in combination with carboplatin and paclitaxel be reimbursed by public drug plans for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy if certain conditions are met. Jemperli in combination with carboplatin and paclitaxel should only be covered to treat adult patients who have primary stage III or IV endometrial cancer, experience a first disease recurrence and have not previously received systemic anticancer therapy for advanced disease, and/or have received prior neoadjuvant adjuvant systemic anticancer therapy and experience a first recurrence at a minimum of 6 months after completion of treatment. Eligible patients should have confirmed dMMR or MSI-H status of their tumours before starting treatment with Jemperli and have a good performance status. Jemperli should only be reimbursed in combination with carboplatin and paclitaxel if prescribed by clinicians with expertise in advanced uterine cancer. Treatment should be supervised and administered in institutions with expertise in systemic therapy delivery. The cost of Jemperli should be reduced.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
